

**BLOOD SCIENCES**  
**DEPARTMENT OF CLINICAL BIOCHEMISTRY**

Title of Document: Guidelines for Therapeutic Drug Monitoring

Q Pulse Reference N<sup>o</sup>: BS/CB/DCB/TOX/3

Authoriser: Peter Beresford

Version N<sup>o</sup>: 8

Page 1 of 2

DRUG	HALF LIFE (approx) (HOURS)	TIME TO STEADY STATE	SAMPLE TIMING	TARGET RANGE	COMMENTS
<b>DIGOXIN</b>	Adults 38-77	6-13 days	At least 6 hours after last dose	0.8 - 2.0 µg/L	1) Half life increased in renal and/or CCF 2) Hypokalaemia potentiates toxicity
<b>PHENYTOIN*</b>	ADULTS 20-40 But highly variable and dependent on dose	Variable 1-2 weeks (dose dependent)	Trough sample	5 – 20 mg/L (Albumin-adjusted)	1) Half life increased in chronic hepatic dysfunction 2) Bioavailability varies between manufacturers
<b>PRIMIDONE</b>	Adults 10-12	2-2.5 days	Immediately	No range for parent drug	Measure Phenobarbitone
<b>SODIUM VALPROATE</b>	Adults 6-17  Children 4-14	3 days  2 days	Before Oral	50 – 100 mg/L	Not routinely available. May be used to assess compliance
<b>CARBAMAZEPINE</b>	Adults and children 5-27	2 weeks or more (1 week after adjusted dose)		4 – 12 mg/L	Threshold for toxicity may be reduced in multiple anticonvulsant therapy <sup>1</sup>
<b>PHENOBARBITONE</b>	Adults 50-120  Infants/Children 40-70	10-25 days  8-15 days		10 – 40 mg/L	Alkaline urine may increase the rate of elimination
<b>LITHIUM</b>	Adults 14-24 (up to 36 in the elderly)	2-4 days	12- 14 hours post dose	Aim for: 0.6 – 0.8 mmol/L normally 0.8 – 1.0 mmol/L if patient has relapsed previously on Li or has sub-syndromal symptoms	1) Half life increased in renal dysfunction 2) Note that not all tablet preparations are slow release <sup>2</sup>
<b>THEOPHYLLINE</b>	Adults (>16yrs): 8.7 (mean average)  Neonates Premature 30 Full term 24	2 days  6 days 5 days	Oral Dosing: 6-7 hours after slow release preparation  2 hours after syrup	10 – 20 mg/L	1) Half-life reduced by up to 50% in smokers 2) Half life increased in hepatic failure

\* See additional notes on Phenytoin reporting

**BLOOD SCIENCES  
DEPARTMENT OF CLINICAL BIOCHEMISTRY**

Title of Document: Guidelines for Therapeutic Drug Monitoring  
Q Pulse Reference N°: BS/CB/DCB/TOX/3  
Authoriser: Peter Beresford

Version N°: 8  
Page 2 of 2

### **Phenytoin reporting.**

All phenytoin results are reported in the following panel, with an Adjusted Phenytoin value, calculated using the Scheiner-Tozer equation (see below) to take into account the effect of protein binding.

Albumin	...	g/L	(35-50)
Phenytoin	...	mg/L	(5-20)
Adjusted Phenytoin	...	mg/L	(5-20)

Albumin-adjusted phenytoin is a better guide to biologically active phenytoin than total levels when albumin is reduced. Interpret results with caution if albumin less than 20g/L or in the presence of other factors that may influence phenytoin binding (eg other highly protein-bound drugs, uraemia, hepatic impairment and pregnancy).

### **Scheiner-Tozer Equation**

To adjust to an albumin concentration of 40g/L:

$$\text{Adjusted Phenytoin} = \frac{\text{Phenytoin}}{\frac{(\text{Alb} \times 0.9) + 0.1}{40}}$$

### **Telephoning Raised Phenytoin Levels**

Adjusted phenytoin greater than 25 mg/L will be phoned.

### **References**

- 1) Clinical Chemistry 1998; 44 (5): 1085 – 1095
- 2) Guidelines to Monitoring Lithium: A statement of good practice 1998  
see also
- 3) NICE guidelines for bipolar disorder (July 2006)
- 4) Fedler C and Stewart MJ. Plasma total phenytoin: a possibly misleading test in developing countries. *Ther Drug Monit.* 1999, **21**: 155-160

For Lamotrigine, Gabapentin, Topiramate and Vigabatrin see: Syva Drug Monitor Vol 2: issues 2, 5 and 10